Trial Profile

An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients with Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pitolisant (Primary)
Indications Idiopathic hypersomnia
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Harmony Biosciences

Most Recent Events

01 Oct 2024 Results presented in a Harmony Biosciences media release.
01 Oct 2024 According to a Harmony Biosciences media release, data from the study will be presented at its Investor Day event today.
30 Aug 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com